近日,亚盛医药(Ascentage Pharma,以下简称“亚盛”)和UNITY Biotechnology(以下简称“UNITY”)宣布在全球范围内共同合作开发基于清除衰老细胞的新型抗衰老治疗药物“Senolytic Therapies”。亚盛医药团队从事针对细胞程序性死亡的小分子靶向药物的研发工作已超过十年,并建立了“best-in-class”抗肿瘤药物化合物库以及临床阶段的靶向抗肿瘤先导化合物。UNITY Biotechnology在ARCH Venture Partners、Venrock和毓承资本的支持下,对于揭示细胞老化和衰老之间的研究工作已进行达四年之久, Recently, Ascentage Pharma and UNITY Biotechnology (hereinafter referred to as “UNITY”) announced that they will jointly work together to develop a new anti-aging treatment based on anti-aging cells “ Senolytic Therapies ”. Asias Pharmaceutical Group has been engaged in the research and development of small molecule targeted drugs for programmed cell death for more than ten years and has established a library of “best-in-class” anti-tumor drug compounds and targeted anti-tumor leaders in clinical stages Compound. UNITY Biotechnology, backed by ARCH Venture Partners, Venrock and YT Capital, has been investigating the effects of cell aging and aging for up to four years,